Affordable Access

deepdyve-link
Publisher Website

Silencing of the SEC62 gene inhibits migratory and invasive potential of various tumor cells.

Authors
  • Greiner, Markus
  • Kreutzer, Birgit
  • Jung, Volker
  • Grobholz, Rainer
  • Hasenfus, Andrea
  • Stöhr, Robert Franz
  • Tornillo, Luigi
  • Dudek, Johanna
  • Stöckle, Michael
  • Unteregger, Gerhard
  • Kamradt, Jörn
  • Wullich, Bernd
  • Zimmermann, Richard
Type
Published Article
Journal
International Journal of Cancer
Publisher
Wiley (John Wiley & Sons)
Publication Date
May 15, 2011
Volume
128
Issue
10
Pages
2284–2295
Identifiers
DOI: 10.1002/ijc.25580
PMID: 20669223
Source
Medline
License
Unknown

Abstract

Sec62 is part of the protein translocation apparatus in the membrane of the endoplasmic reticulum (ER). In yeast, Sec62 participates in the post-translational translocation of proteins into the ER, but its function in mammals remains elusive. Previously we described the amplification and over-expression of the SEC62 gene in prostate cancer cell lines and the protein has been described as a potential target gene in prostate cancer. In the current study we show that in the tumor tissue of prostate cancer patients Sec62 protein levels are elevated compared with tumor-free tissue derived from the same patients or from prostates of control group patients and that the higher Sec62 protein content correlates with an increasing de-differentiation of the cells. Therefore, up-regulation of Sec62 protein content indeed is a phenomenon associated with prostate cancer progression. Analysis of a multi-tissue tumor array showed that in addition to prostate cancer, overproduction of Sec62 is observed in various other tumors, most significantly in tumors of the lung and the thyroid. To examine the tumor-related functions of Sec62, we silenced the SEC62 gene in the prostate cancer cell-line PC3 as well as in a set of other tumor cell-lines with two different siRNAs. In general, after silencing of SEC62 the cell migration and the invasive potential of the cells was blocked or at least dramatically reduced while cell viability was hardly affected. Thus, the SEC62 gene may indeed be considered as a target gene in the therapy of various tumors.

Report this publication

Statistics

Seen <100 times